Equity Profile

AUPH

Aurinia Pharmaceuticals Inc.

Health CareBiotechnology$2.1B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Aurinia Pharmaceuticals Inc. is a biotechnology company focused on developing therapies for kidney diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercial success of its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

AUPH Q2-2026 Earnings Preview

Context

Company Snapshot

Aurinia Pharmaceuticals Inc. is a biotechnology company focused on developing therapies for kidney diseases. With a market cap of $2 billion, it plays a significant role in the healthcare sector, particularly in addressing unmet medical needs in autoimmune and inflammatory conditions.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+142.91%

Avg Stock Reaction

+0.41%

Last Quarter Recap

In Q1 2026, Aurinia reported an EPS of $0.25, exceeding expectations by 38.89%. However, the stock price fell by 6.80% the following day, indicating market skepticism despite the positive earnings surprise.

Management Promises & Guidance

Continued focus on expanding the market for its lead product.
Commitment to advancing clinical trials for new therapies.
Plans to enhance operational efficiencies.

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the upcoming earnings report, given the company's recent strong EPS performance. However, the lack of revenue guidance raises concerns about future growth.

Bull Case

If Aurinia can demonstrate strong revenue growth alongside its positive EPS trend, it could significantly boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the earnings report reveals disappointing revenue numbers or lack of guidance, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue growth rate compared to last quarter?

Revenue growth will indicate the company's ability to capitalize on its product offerings and market demand.

Will management provide guidance for the upcoming quarters?

Guidance is crucial for setting investor expectations and assessing the company's future performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Aurinia's potential for strong revenue growth driven by recent product launches and market expansion efforts.

Supporting Evidence

Aurinia's recent EPS surprises indicate strong underlying performance.

The options market is pricing a significant move, suggesting heightened investor interest.

The company's historical ability to beat earnings expectations supports a more optimistic outlook.

Key Risk

If revenue growth exceeds expectations, it could significantly shift market sentiment in favor of the company.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's recent earnings surprises against its ability to sustain growth and provide clear guidance.

Bull Confirmed If

Revenue growth of at least 15% quarter-over-quarter would confirm the bullish outlook.

Bear Confirmed If

Any revenue decline or lack of guidance would support a bearish view.

Pre-Earnings Positioning

Options Market

Implied Move

±23.81%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±23.8% while AUPH has averaged ±5.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

38.5%

Calls (23K)P/C Ratio: 0.02Puts (400)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.6%, with a raw directional average of +3.4% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Aurinia beats expectations and raises guidance, history suggests the stock could rise by around 1.03% on the following day.

In-Line / Cautious

If results are in line but management is cautious, the stock may experience muted movement as investors reassess their outlook.

Miss

If the company misses expectations, history suggests a potential decline of about 1.44% in the stock price.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the commercial performance of its lead product.
2Details on ongoing clinical trials and their expected outcomes.
3Management's outlook on market conditions and competitive landscape.
4Insights into operational efficiencies and cost management strategies.
5Any changes to the company's strategic priorities or focus areas.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Aurinia Pharmaceuticals Inc. is a biotechnology company focused on developing therapies for kidney diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and commercial success of its products.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

AUPH Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+142.91%

Avg Stock Reaction

+0.41%

Last Quarter Recap

Management Promises & Guidance

Continued focus on expanding the market for its lead product.
Commitment to advancing clinical trials for new therapies.
Plans to enhance operational efficiencies.

Expectations

Wall Street Expectations

Bull Case

If Aurinia can demonstrate strong revenue growth alongside its positive EPS trend, it could significantly boost investor confidence and drive the stock higher.

Bear Case

Conversely, if the earnings report reveals disappointing revenue numbers or lack of guidance, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the revenue growth rate compared to last quarter?

Revenue growth will indicate the company's ability to capitalize on its product offerings and market demand.

Will management provide guidance for the upcoming quarters?

Guidance is crucial for setting investor expectations and assessing the company's future performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Aurinia's potential for strong revenue growth driven by recent product launches and market expansion efforts.

Supporting Evidence

Aurinia's recent EPS surprises indicate strong underlying performance.

The options market is pricing a significant move, suggesting heightened investor interest.

The company's historical ability to beat earnings expectations supports a more optimistic outlook.

Key Risk

If revenue growth exceeds expectations, it could significantly shift market sentiment in favor of the company.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the company's recent earnings surprises against its ability to sustain growth and provide clear guidance.

Bull Confirmed If

Revenue growth of at least 15% quarter-over-quarter would confirm the bullish outlook.

Bear Confirmed If

Any revenue decline or lack of guidance would support a bearish view.

Pre-Earnings Positioning

Options Market

Implied Move

±23.81%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant potential move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±23.8% while AUPH has averaged ±5.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

38.5%

Calls (23K)P/C Ratio: 0.02Puts (400)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Aurinia beats expectations and raises guidance, history suggests the stock could rise by around 1.03% on the following day.

In-Line / Cautious

If results are in line but management is cautious, the stock may experience muted movement as investors reassess their outlook.

Miss

If the company misses expectations, history suggests a potential decline of about 1.44% in the stock price.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the commercial performance of its lead product.
2Details on ongoing clinical trials and their expected outcomes.
3Management's outlook on market conditions and competitive landscape.
4Insights into operational efficiencies and cost management strategies.
5Any changes to the company's strategic priorities or focus areas.